Eleonora Di Zanni
Master degree in Medical and Pharmaceutical Biotechnology, University of Genoa (2008);
PhD in Clinics, Genetics and Immunology of childhood diseases (2012);
Post-doc at in Laboratory of Molecular Genetics, Gaslini Institute, Genova (2012-2015);
Post-doc at Biophysics Institute (Cnr-Ibf) Genova (2015 – today)
orcid://0000-0003-4564-2202, ncbi://54215388
Research interests:
Key publications:
Di Zanni E, Gradogna A, Scholz-Starke J, Boccaccio A (2018) Gain of function of TMEM16E/ANO5 scrambling activity caused by a mutation associated with gnathodiaphyseal dysplasia. Cellular and Molecular Life Sciences 75:1657-1670. doi: 10.1007/s00018-017-2704-9
Di Zanni E, Bianchi G, Ravazzolo R, et al (2017) Targeting of PHOX2B expression allows the identification of drugs effective in counteracting neuroblastoma cell growth. Oncotarget. 8:72133-72146. doi: 10.18632/oncotarget.19922
Carpaneto A, Boccaccio A, Lagostena L, Di Zanni E, Scholz-Starke J (2017) The signaling lipid phosphatidylinositol-3,5-bisphosphate targets plant CLC-a anion/H+ exchange activity. EMBO Rep. 18:1100-1107. doi: 10.15252/embr.201643814
Bachetti T, Chiesa S, Castagnola P, Bani D, Di Zanni E, et al. (2013). Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Ann Rheum Dis.72:1044-52. doi: 10.1136/annrheumdis-2012-201952
Di Zanni E, Bachetti T, Parodi S, et al. (2012) In vitro drug treatments reduce the deleterious effects of aggregates containing polyAla expanded PHOX2B proteins. Neurobiol Dis. 45:508-18. doi: 10.1016/j.nbd.2011.09.007